SCHEMBL4359936

SCHEMBL4359936

Cc1cccc(C)c1NC(=O)Nc1cc(Cl)ccc1O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNMA1 Q12791 7/20 0.62
TRPV1 Q8NER1 1/20 0.58
NTRK1 P04629 1/20 0.55
CDK19 Q9BWU1 1/20 0.55
POLB P06746 1/20 0.51
GRIK1 P39086 2/20 0.51
CHRNA7 P36544 1/20 0.51
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
HPGD P15428 1/20 0.50
MAPT P10636 2/20 0.49
CA12 O43570 2/20 0.49
CA1 P00915 2/20 0.49
CA2 P00918 2/20 0.49
CA9 Q16790 2/20 0.49
IDH1 O75874 1/20 0.49
PKM P14618 1/20 0.49
HTT P42858 1/20 0.49
LMNA P02545 1/20 0.49
GAA P10253 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4358434 0.87 KCNMA1 (0.68) KCNMA1TRPV1NTRK1CDK19POLB
SCHEMBL28295632 0.84 KCNMA1 (0.68) KCNMA1NTRK1CDK19POLBGRIK1
SCHEMBL5193843 0.83 GRIK1 (0.67) GRIK1
SCHEMBL4348752 0.81 TRPV1 (0.47) TRPV1POLBMEN1KMT2AMAPT
SCHEMBL1463258 0.80 NTRK1 (0.67) KCNMA1TRPV1NTRK1CDK19GRIK1
SCHEMBL1463506 0.79 GRIK1 (0.73) KCNMA1TRPV1NTRK1CDK19GRIK1
SCHEMBL5214889 0.79 PYGL (0.67) KCNMA1GRIK1
SCHEMBL7254163 0.78 KCNMA1 (0.60) KCNMA1NTRK1CDK19POLBGRIK1
SCHEMBL1883575 0.77 GRIK1 (0.70) KCNMA1NTRK1CDK19POLBGRIK1
SCHEMBL4341663 0.77 CXCR1 (0.59) TRPV1POLBKMT2AMAPTCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
CN-100546977-C Suppress the new compound and the application thereof of rotamase JERINI AG (DE) 2009-10-07 CN claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
EP-1402887-A1 New compounds for the inhibition of undesired cell proliferation and use thereof Jerini AG (DE) 2004-03-31 EP claimed
EP-1402888-A1 The use of substituted carbocyclic compounds as rotamases inhibitors Jerini AG (DE) 2004-03-31 EP claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 KCNMA1 1006/4885TRPV1 2328/4885NTRK1 2802/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 KCNMA1 1809/4885TRPV1 2320/4885NTRK1 3171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.